Bianfei Shao, Fang Liu, Zhongzheng Xiang, Yuanyuan Zeng, Tian Yang, Tao He, Jiachun Ma, Xiran Wang, Siting Yu, Lei Liu
Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China.
Department of Radiation Oncology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Future Oncol. 2022 Sep;18(27):3101-3118. doi: 10.2217/fon-2022-0022. Epub 2022 Sep 6.
Cherenkov radiation (CR) is the characteristic blue glow that is generated during radiotherapy or radioisotope decay. Its distribution and intensity naturally reflect the actual dose and field of radiotherapy and the location of radioisotope imaging agents . Therefore, CR can represent a potential light source for radiotherapy monitoring and radioisotope-based tumor imaging. When used in combination with new imaging techniques, molecular probes or nanomedicine, CR imaging exhibits unique advantages (accuracy, low cost, convenience and fast) in tumor radiotherapy monitoring and imaging. Furthermore, photosensitive nanomaterials can be used for CR photodynamic therapy, providing new approaches for integrating tumor imaging and treatment. Here the authors review the latest developments in the use of CR in tumor research and discuss current challenges and new directions for future studies.
切伦科夫辐射（CR）是在放射治疗或放射性同位素衰变过程中产生的特有的蓝色辉光。其分布和强度自然地反映了放射治疗的实际剂量和射野以及放射性同位素显像剂的位置。因此，CR可成为放射治疗监测和基于放射性同位素的肿瘤成像的潜在光源。当与新的成像技术、分子探针或纳米药物联合使用时，CR成像在肿瘤放射治疗监测和成像方面具有独特优势（准确性、低成本、便利性和快速性）。此外，光敏纳米材料可用于CR光动力治疗，为肿瘤成像与治疗的整合提供了新方法。本文作者综述了CR在肿瘤研究应用中的最新进展，并讨论了当前面临的挑战以及未来研究的新方向。
